Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Phase I Trial of MB-CART20.1 for the Treatment of Patients With Metastatic Melanoma

NCT03893019 is registered in ClinicalTrials.gov with Miltenyi Biomedicine GmbH as lead sponsor.

NCT NCT03893019
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03893019 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Phase I Trial of MB-CART20.1 for the Treatment of Patients With Metastatic Melanoma
Lead sponsor
Miltenyi Biomedicine GmbH
Phase
Phase 1
Overall status
Terminated
Start date
March 8, 2019
Completion date
January 30, 2023
Enrollment
9 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma (skin)